Literature DB >> 26461001

Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-α and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models.

Nathan A Koonce1, Charles M Quick2, Matthew E Hardee1, Azemat Jamshidi-Parsian1, Judith A Dent1, Giulio F Paciotti3, Dmitry Nedosekin4, Ruud P M Dings1, Robert J Griffin5.   

Abstract

PURPOSE: Although remarkable preclinical antitumor effects have been shown for tumor necrosis factor-α (TNF) alone and combined with radiation, its clinical use has been hindered by systemic dose-limiting toxicities. We investigated the physiological and antitumor effects of radiation therapy combined with the novel nanomedicine CYT-6091, a 27-nm average-diameter polyethylene glycol-TNF-coated gold nanoparticle, which recently passed through phase 1 trials. METHODS AND MATERIALS: The physiologic and antitumor effects of single and fractionated radiation combined with CYT-6091 were studied in the murine 4T1 breast carcinoma and SCCVII head and neck tumor squamous cell carcinoma models.
RESULTS: In the 4T1 murine breast tumor model, we observed a significant reduction in the tumor interstitial fluid pressure (IFP) 24 hours after CYT-6091 alone and combined with a radiation dose of 12 Gy (P<.05 vs control). In contrast, radiation alone (12 Gy) had a negligible effect on the IFP. In the SCCVII head and neck tumor model, the baseline IFP was not markedly elevated, and little additional change occurred in the IFP after single-dose radiation or combined therapy (P>.05 vs control) despite extensive vascular damage observed. The IFP reduction in the 4T1 model was also associated with marked vascular damage and extravasation of red blood cells into the tumor interstitium. A sustained reduction in tumor cell density was observed in the combined therapy group compared with all other groups (P<.05). Finally, we observed a more than twofold delay in tumor growth when CYT-6091 was combined with a single 20-Gy radiation dose-notably, irrespective of the treatment sequence. Moreover, when hypofractionated radiation (12 Gy × 3) was applied with CYT-6091 treatment, a more than five-fold growth delay was observed in the combined treatment group of both tumor models and determined to be synergistic.
CONCLUSIONS: Our results have demonstrated that TNF-labeled gold nanoparticles combined with single or fractionated high-dose radiation therapy is effective in reducing IFP and tumor growth and shows promise for clinical translation.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26461001      PMCID: PMC4934370          DOI: 10.1016/j.ijrobp.2015.07.2275

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  34 in total

1.  A quantitative analysis of the direct and indirect action of X radiation on malignant cells.

Authors:  I LASNITZKI
Journal:  Br J Radiol       Date:  1947-06       Impact factor: 3.039

2.  Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.

Authors:  Mithun M Shenoi; Isabelle Iltis; Jeunghwan Choi; Nathan A Koonce; Gregory J Metzger; Robert J Griffin; John C Bischof
Journal:  Mol Pharm       Date:  2013-04-17       Impact factor: 4.939

3.  The use of gold nanoparticles to enhance radiotherapy in mice.

Authors:  James F Hainfeld; Daniel N Slatkin; Henry M Smilowitz
Journal:  Phys Med Biol       Date:  2004-09-21       Impact factor: 3.609

Review 4.  Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS).

Authors:  Heon Joo Park; Robert J Griffin; Susanta Hui; Seymour H Levitt; Chang W Song
Journal:  Radiat Res       Date:  2012-01-09       Impact factor: 2.841

Review 5.  High interstitial fluid pressure - an obstacle in cancer therapy.

Authors:  Carl-Henrik Heldin; Kristofer Rubin; Kristian Pietras; Arne Ostman
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

6.  Tumor necrosis factor alpha (TNF-alpha) gene therapy targeted by ionizing radiation selectively damages tumor vasculature.

Authors:  H J Mauceri; N N Hanna; J D Wayne; D E Hallahan; S Hellman; R R Weichselbaum
Journal:  Cancer Res       Date:  1996-10-01       Impact factor: 12.701

7.  Phase I clinical trial of recombinant human tumor necrosis factor in children with refractory solid tumors: a Pediatric Oncology Group study.

Authors:  W L Furman; D Strother; K McClain; B Bell; B Leventhal; C B Pratt
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

8.  Correlations of noninvasive BOLD and TOLD MRI with pO2 and relevance to tumor radiation response.

Authors:  Rami R Hallac; Heling Zhou; Rajesh Pidikiti; Kwang Song; Strahinja Stojadinovic; Dawen Zhao; Timothy Solberg; Peter Peschke; Ralph P Mason
Journal:  Magn Reson Med       Date:  2013-06-27       Impact factor: 4.668

9.  Biodistribution of TNF-alpha-coated gold nanoparticles in an in vivo model system.

Authors:  Raghav Goel; Neha Shah; Rachana Visaria; Giulio F Paciotti; John C Bischof
Journal:  Nanomedicine (Lond)       Date:  2009-06       Impact factor: 5.307

10.  Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts.

Authors:  C A Kristensen; M Nozue; Y Boucher; R K Jain
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

View more
  20 in total

1.  The Future of Radiobiology.

Authors:  David G Kirsch; Max Diehn; Aparna H Kesarwala; Amit Maity; Meredith A Morgan; Julie K Schwarz; Robert Bristow; Sandra Demaria; Iris Eke; Robert J Griffin; Daphne Haas-Kogan; Geoff S Higgins; Alec C Kimmelman; Randall J Kimple; Isabelle M Lombaert; Li Ma; Brian Marples; Frank Pajonk; Catherine C Park; Dörthe Schaue; Phuoc T Tran; Eric J Bernhard
Journal:  J Natl Cancer Inst       Date:  2018-04-01       Impact factor: 13.506

2.  Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in vivo flow cytometry.

Authors:  Nathan A Koonce; Mazen A Juratli; Chengzhong Cai; Mustafa Sarimollaoglu; Yulian A Menyaev; Judith Dent; Charles M Quick; Ruud P M Dings; Dmitry Nedosekin; Vladimir Zharov; Robert J Griffin
Journal:  Biochem Biophys Res Commun       Date:  2017-08-16       Impact factor: 3.575

3.  Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice.

Authors:  Gunnar Boysen; Azemat Jamshidi-Parsian; Mary A Davis; Eric R Siegel; Christine M Simecka; Rajshekhar A Kore; Ruud P M Dings; Robert J Griffin
Journal:  Int J Radiat Biol       Date:  2019-01-15       Impact factor: 2.694

Review 4.  Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.

Authors:  Andrew T Lucas; Lauren Sl Price; Allison Schorzman; William C Zamboni
Journal:  Nanomedicine (Lond)       Date:  2017-07-26       Impact factor: 5.307

5.  Galectin-1-based tumour-targeting for gold nanostructure-mediated photothermal therapy.

Authors:  Samir V Jenkins; Dmitry A Nedosekin; Emily K Miller; Vladimir P Zharov; Ruud P M Dings; Jingyi Chen; Robert J Griffin
Journal:  Int J Hyperthermia       Date:  2017-05-09       Impact factor: 3.914

Review 6.  Next-generation engineered nanogold for multimodal cancer therapy and imaging: a clinical perspectives.

Authors:  Madhusudhan Alle; Garima Sharma; Seung-Hwan Lee; Jin-Chul Kim
Journal:  J Nanobiotechnology       Date:  2022-07-02       Impact factor: 9.429

7.  Synthesis and Evaluation of Paclitaxel-Loaded Gold Nanoparticles for Tumor-Targeted Drug Delivery.

Authors:  Giulio F Paciotti; Jielu Zhao; Shugeng Cao; Peggy J Brodie; Lawrence Tamarkin; Marja Huhta; Lonnie D Myer; Jay Friedman; David G I Kingston
Journal:  Bioconjug Chem       Date:  2016-10-18       Impact factor: 4.774

8.  Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors.

Authors:  Naris Nilubol; ZiQiang Yuan; Giulio F Paciotti; Lawrence Tamarkin; Carmen Sanchez; Kelli Gaskins; Esther M Freedman; Shugeng Cao; Jielu Zhao; David G I Kingston; Steven K Libutti; Electron Kebebew
Journal:  J Natl Cancer Inst       Date:  2018-09-01       Impact factor: 13.506

Review 9.  The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches.

Authors:  Daniel Cruceriu; Oana Baldasici; Ovidiu Balacescu; Ioana Berindan-Neagoe
Journal:  Cell Oncol (Dordr)       Date:  2020-01-03       Impact factor: 6.730

Review 10.  Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer.

Authors:  Isela Martínez-Reza; Lorenza Díaz; Rocío García-Becerra
Journal:  J Biomed Sci       Date:  2017-12-04       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.